Evaluation of efficacy and safety of combinationtherapy with trastuzumab and eribulin for HER2-positive inoperableness or metastatic breast cancer
Not Applicable
Recruiting
- Conditions
- inoperableness or metastatic breast cancer
- Registration Number
- JPRN-UMIN000007113
- Lead Sponsor
- Wakayama Medical University Department of Thoracic and Cardiovascular Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
(1)With serious drug allergy (2) Systemic infection (3) Control of pleural effusion, ascites and pericardial fluid (4)Clinical symptoms with brain metastasis (5) Severe complications 1) Control of bad heart disease 2) Myocardial infarction within 6 months 3) Cirrhosis 4) Between interstitial Pneumonitis and pulmonary fibrosis 5) Bleeding tendency (6) Active cancer (7) Pregnancy, breast feeding or wish of future bearing (8) Long-term corticosteroid therapy (9) Wide range of radiation therapy (10)Refusal of blood transfusion (11) Patients considered inappropriate by the study investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method